Regeneus Ltd

RGS.AU

$0.01

Closing

0.00

1D

▲166.67%

YTD

Market cap

$3.93M

52 week high

$0.01

52 week low

$0.00

Volume

50,000

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$3.93M

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

-0.80

Revenue Growth (Annual)

0.00%

52 week high

$0.01

52 week low

$0.00

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Regeneus Ltd is an Australia-based clinical-stage regenerative medicine company. The Company uses stem cell technologies to develop a portfolio of novel cell-based therapies. The Company develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.